AKT1 and glioblastoma: To assess the effect of dual inhibiting OCT4 and AKT on cancer cells of somatic origin, we chose two human glioblastoma cell lines (U87 and U251) that are known to express low levels of OCT419, 20, infected them with sh-OCT4, and then treated them with Akti-1/2.